Melodyn (Buprenorphine)

Buprenorphine acts as a high‑affinity partial agonist at the µ‑opioid receptor, generating analgesia while limiting the ceiling effect on respiratory depression. It also antagonizes or partially stimulates the κ‑opioid receptor, which contributes to pain relief and reduces dysphoric effects. The transdermal system releases the drug through the skin into systemic circulation.

The specific dose and patch strength are determined by the prescribing clinician based on the patient’s pain severity, prior opioid exposure, and clinical response. The prescriber selects the appropriate patch size and replacement interval, and the patient should follow the healthcare professional’s instructions without alteration.

Limited clinical data exist for buprenorphine use during pregnancy and lactation. Because opioids can affect fetal development and may be excreted in breast milk, the medication should only be used if the potential benefit outweighs the risk. Pregnant or nursing patients should discuss alternatives and risks with their healthcare provider.

To request Melodyn, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Compared with full µ‑opioid agonists such as morphine, buprenorphine has a ceiling effect on respiratory depression, which may improve safety in opioid‑tolerant patients. Its partial agonist profile also reduces the risk of severe constipation and dependence, while still delivering potent analgesia. However, individual response varies, and clinicians must assess suitability on a case‑by‑case basis.

Melodyn patches should be stored at room temperature, below 25 °C, in their original packaging to protect from moisture and light. Keep the product out of reach of children and do not expose it to extreme heat or direct sunlight. Used patches contain residual drug and must be folded with the adhesive sides together before disposal in accordance with local regulations.

The patch is applied to clean, dry, hair‑free skin on the upper torso or upper arm, avoiding areas with irritation or excessive movement. Press firmly for about 30 seconds to ensure good contact. After the prescribed wear period (usually 7 days), remove the patch by peeling it off slowly, fold it adhesive side inward, and dispose of it safely. Do not reuse.

The most serious risks associated with Melodyn include respiratory depression, especially in opioid‑naïve individuals or when combined with other CNS depressants; severe hypotension; and allergic reactions such as rash, urticaria, or angioedema. Patients should be educated to seek immediate medical attention if they experience difficulty breathing, faintness, or signs of an allergic response.

Melodyn is contraindicated in patients with known hypersensitivity to buprenorphine or any patch components, in those with severe respiratory insufficiency, and in individuals who are not opioid‑tolerant. Caution is also advised for patients with significant hepatic impairment, uncontrolled asthma, or concurrent use of strong CYP3A4 inhibitors. Clinicians must evaluate each patient’s medical history before prescribing.